After propensity score matching, the risks for death, hospitalization for heart failure, MI and stroke were analyzed in 235,064 patients of each group, newly initiated on either SGLT2 inhibitors (dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin and luseogliflozin) or other glucose-lowering drugs. This evidence concerns the gene SLC5A2 and stroke disorder.